392 material Form 8-K filings that 341 companies we cover made with the SEC in July 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
CorVel reported results for the quarter ended June 30, 2024, in a press release furnished as Exhibit 99.1. Revenue rose to $212 million from $190 million a year earlier, net income rose to $21.6 million from $19.8 million, and diluted earnings per share rose to $1.25 from $1.14. Revenue, profit and per-share earnings all improved year over year.
Revenue of $212 million for the quarter, up from $190 million in the June 2023 quarter
Diluted EPS of $1.25, compared with $1.14 a year earlier
Gross profit of $48.2 million at a 22.7% gross margin, up from $41.9 million
Repurchased $9.5 million of common stock; ended the quarter with $132 million in cash and no borrowings
NewMarket reported second-quarter 2024 net income of $111.6 million, or $11.63 per share, up from $99.6 million, or $10.36 per share, a year earlier. Total net sales rose to $710.2 million from $685.1 million, with the increase including its newly acquired AMPAC specialty materials business, while petroleum additives sales fell slightly. The results are a routine quarterly update, and the filing does not include new guidance.
Q2 2024 net income was $111.6 million, or $11.63 per share, versus $99.6 million, or $10.36 per share, in Q2 2023.
Petroleum additives operating profit was $147.8 million, up from $132.1 million, mainly due to lower raw material and operating costs and higher shipments, partly offset by lower selling prices.
Petroleum additives sales were $669.8 million, down from $684.0 million, while specialty materials (AMPAC) added $38.0 million in sales.
Net Debt to EBITDA was 1.6 as of June 30, 2024, after the AMPAC acquisition completed on January 16, 2024; long-term debt was $1.17 billion.
Centerspace reported second-quarter 2024 results and raised the midpoint of its 2024 Core FFO per diluted share outlook, narrowing the range to $4.78 to $4.92 from $4.74 to $4.92. Q2 net loss was $0.19 per diluted share, compared with a $0.23 loss a year earlier, while Core FFO per diluted share was $1.27 versus $1.28 in the prior-year quarter.
Updated 2024 Core FFO per diluted share outlook: $4.78 to $4.92, up from $4.74 to $4.92; net income per diluted share outlook raised to $(1.21) to $(1.01) from $(1.34) to $(1.10)
Q2 2024 net loss of $0.19 per diluted share vs. $0.23 loss in Q2 2023; Q2 Core FFO of $1.27 per diluted share vs. $1.28
Six-month Core FFO per diluted share rose 5.5% to $2.49; same-store NOI rose 2.4% in Q2 2024 year over year
Unsecured credit facility maturity extended to July 2028 on July 26, 2024; borrowing capacity stayed at $250.0 million
COPT Defense Properties reported results for the quarter ended June 30, 2024, with net income of $36.4 million, up from $31.6 million in the same quarter of 2023. Diluted FFO per share rose to $0.64 from $0.60, and the company's quarterly dividend per common share was $0.295, up from $0.285 a year earlier.
Q2 2024 total revenues were $187.3 million, compared with $169.2 million in Q2 2023.
Diluted EPS was $0.31, compared with $0.27 in Q2 2023. Net income was $36.4 million.
NOI from real estate operations was $105.4 million, compared with $95.0 million in Q2 2023.
Dividend per common share was $0.295 for the quarter, compared with $0.285 a year earlier.
CNO Financial Group reported second-quarter 2024 net income of $116.3 million, or $1.06 per diluted share, up from $73.7 million, or $0.64 per diluted share, a year earlier. Net operating income rose to $114.6 million, or $1.05 per diluted share, and the company said it is raising full-year guidance on earnings and cash flow. The company returned $77.2 million to shareholders in the quarter through buybacks and dividends.
Net income of $116.3 million, or $1.06 per diluted share, in 2Q24 versus $73.7 million, or $0.64, in 2Q23
Net operating income of $114.6 million, or $1.05 per diluted share, in 2Q24 versus $62.3 million, or $0.54, in 2Q23
Full-year guidance raised on earnings and cash flow
Repurchased $60.0 million of common stock in 2Q24; 106.5 million shares outstanding at June 30, 2024
Element Solutions reported second-quarter 2024 net sales of $613 million, up 5% from a year earlier, and net income of $93 million versus $30 million in the same quarter of 2023. GAAP diluted EPS was $0.38 compared with $0.11, and adjusted EBITDA rose 16% to $135 million. The company also said it raised its full-year 2024 adjusted EBITDA guidance to $530 million to $545 million, which supports the earnings trend for shareholders.
Net sales $613 million, up 5% reported and 4% organic; Electronics up 10% to $392 million
GAAP diluted EPS $0.38 vs $0.11; adjusted EPS $0.36 vs $0.31 a year earlier
Adjusted EBITDA $135 million, up 16%; Industrial & Specialty net sales down 4% to $221 million
Full-year 2024 adjusted EBITDA guidance raised to $530 million to $545 million; free cash flow expected $280 million to $300 million
SBA Communications reported second-quarter 2024 total revenues of $660.5 million, down 2.7%, and net income of $159.5 million, or $1.51 per diluted share, down from $1.87 a year earlier. The company also lowered its full-year 2024 revenue and Adjusted EBITDA outlook, which weighs on shareholders, while declaring a $0.98 quarterly dividend.
Q2 2024 total revenues were $660.5 million, down from $678.5 million; net income was $159.5 million, or $1.51 per diluted share, versus $202.0 million, or $1.87, in Q2 2023
Net income included a $66.2 million after-tax loss on currency remeasurement of intercompany loans
Full-year 2024 total revenue outlook is now $2,642.0 million to $2,672.0 million, a $20.0 million cut at the midpoint; Adjusted EBITDA outlook is $1,876.0 million to $1,896.0 million, down $13.0 million at the midpoint
Quarterly dividend of $0.98 per share is payable September 18, 2024 to holders of record on August 22, 2024
Merchants Bancorp reported second quarter 2024 net income of $76.4 million, or $1.49 per diluted share, up 17% and 14% from the second quarter of 2023 but down 12% and 17% from the first quarter of 2024. Total assets reached $18.2 billion and tangible book value per share rose 30% year over year to $31.27.
Net income of $76.4 million, up 17% from $65.3 million a year earlier and down 12% from $87.1 million in Q1 2024
Diluted EPS of $1.49, up from $1.31 a year earlier and down from $1.80 in Q1 2024
Total assets of $18.2 billion at June 30, 2024; tangible book value per share of $31.27, up 30% from $24.14
Non-performing loans rose to $143.5 million, or 1.30% of gross loans, from $131.8 million (1.22%) at March 31, 2024
AMERISAFE reported second-quarter 2024 net income of $11.0 million, down 29.7% from $15.6 million a year earlier, and diluted EPS of $0.57, down from $0.81. Net premiums earned rose 4.6% to $68.6 million, but higher loss and expense costs cut underwriting profit by 31.2% to $6.5 million, so shareholders saw lower per-share earnings even as the insurer wrote more business.
Diluted EPS was $0.57 for the quarter, versus $0.81 in Q2 2023; operating EPS was $0.58, versus $0.73.
Net premiums earned rose 4.6% to $68.6 million, while the net combined ratio worsened to 90.5% from 85.4%.
Favorable prior accident year reserve development reduced loss expenses by $8.1 million.
The Board declared a quarterly dividend of $0.37 per share on July 26, 2024, payable September 20, 2024; a conference call is set for July 30, 2024.
Corcept Therapeutics reported second-quarter 2024 revenue of $163.8 million, up 39% from a year earlier, and raised its full-year 2024 revenue guidance to $640 million to $670 million from $620 million to $650 million. Diluted earnings per share were $0.32, compared with $0.25 in the second quarter of 2023, though operating expenses rose to $128.2 million from $88.1 million.
Q2 2024 revenue of $163.8 million, versus $117.7 million in Q2 2023
Diluted EPS of $0.32 versus $0.25; net income of $35.5 million versus $27.5 million
2024 revenue guidance raised to $640 million to $670 million from $620 million to $650 million
Cash and investments of $492.5 million at June 30, 2024, up from $451.0 million at March 31, 2024
Rambus reported second-quarter 2024 results for the period ended June 30, 2024, with GAAP revenue of $132.1 million, up from $119.8 million a year earlier, and operating income of $40.3 million, up from $11.7 million. Net income fell to $36.1 million, or $0.33 per diluted share, from $168.9 million, or $1.51, a year earlier, when the company recorded an income tax benefit of $155.3 million. Shareholders get higher revenue and operating income, but reported earnings declined against a prior-year period that included that tax benefit, and the company said it expects a strong third quarter.
GAAP revenue was $132.1 million versus $119.8 million in Q2 2023; product revenue was $56.7 million and royalties were $56.4 million.
Net income was $36.1 million, or $0.33 per diluted share, versus $168.9 million, or $1.51, in Q2 2023, which included a $155.3 million income tax benefit.
Cash from operating activities was $70.4 million, versus $50.4 million a year earlier; cash and marketable securities totaled $432.9 million at June 30, 2024.
Third-quarter 2024 outlook calls for product revenue of $62 million to $68 million and licensing billings of $60 million to $66 million; full revenue guidance will be discussed on the conference call.
Lattice Semiconductor reported second-quarter 2024 revenue of $124.1 million, down 11.9% from the first quarter and 34.7% from a year earlier, with GAAP diluted earnings of $0.16 per share. The company guided third-quarter 2024 revenue to between $117 million and $137 million, and interim CEO Esam Elashmawi said the industry is starting to show signs of improvement after a period of inventory normalization.
Q2 2024 revenue was $124.1 million, down 11.9% from Q1 2024 and down 34.7% from Q2 2023.
GAAP diluted EPS was $0.16 versus $0.11 in Q1 2024 and $0.36 in Q2 2023; non-GAAP diluted EPS was $0.23 versus $0.29 in Q1 2024.
Q3 2024 outlook: revenue of $117 million to $137 million, non-GAAP gross margin of 69.0% plus or minus 1%, and non-GAAP operating expenses of $53 million to $55 million.
The company repurchased shares for the fifteenth consecutive quarter, with $30.0 million of buybacks in the first half of 2024.
Minerals Technologies furnished the transcript and slides from its July 26, 2024 second-quarter earnings call as Exhibits 99.1 and 99.2, because a third-party webcast problem meant some listeners could not hear part of the audio. The call showed higher operating income and earnings per share excluding special items, offset by $34 million in special charges, mainly a $30 million provision for a credit loss on a line of credit to BMI Oldco, the entity formerly known as BMI.
Q2 2024 sales were $541 million, up 1% on an underlying basis; operating income was $85 million, up 20%, with operating margin of 15.7%.
Earnings per share were $1.65 excluding special items, up 26% from the prior year; special charges totaled $34 million.
The $34 million in special charges mainly reflects a $30 million provision for credit loss on a committed line of credit to BMI Oldco, of which $5 million has been loaned so far.
For Q3 2024, the company expects sales of $535 million to $545 million, operating income of $77 million to $80 million, and EPS of $1.50 to $1.55.
Revvity reported second-quarter 2024 revenue of $692 million, down from $709 million a year earlier, while GAAP EPS rose to $0.45 from $0.28 and adjusted EPS from continuing operations was $1.22 versus $1.21. The company raised its full-year 2024 adjusted EPS guidance to $4.70-$4.80 and set revenue guidance at $2.77-$2.79 billion, citing currency changes and assumed 2% organic revenue growth. Shareholders see higher profit measures alongside a lower top line, with Life Sciences revenue down 7%.
Q2 2024 revenue was $692 million versus $709 million a year earlier; reported revenue fell 2% and organic revenue fell 1%.
GAAP EPS was $0.45 versus $0.28; adjusted EPS from continuing operations was $1.22 versus $1.21.
Full-year 2024 adjusted EPS guidance raised to $4.70-$4.80; revenue guidance updated to $2.77-$2.79 billion.
Life Sciences revenue fell 7% to $314 million; Diagnostics revenue rose 1% to $378 million.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.